Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Conditionally active biologic anti-AXL antibody drug conjugate”In the company’s words, NCT04681131 on ClinicalTrials.gov
- Tested for
- Non-Small-Cell Lung Cancer, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- Main trialPhase 2
- “The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC”In the company’s words, NCT04681131 on ClinicalTrials.gov
- Other names
- BA3011
Other drugs for Non-Small-Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 9 Jul 2025 | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | |
| Phase 1/2Completed | 8 Jan 2025 | CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026